About Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E Ratio-30.9901960784314
Forward P/E Ratio-20.59
Sales & Book Value
Annual Sales$5.42 million
Price / Sales753.86
Price / CashN/A
Book Value$6.17 per share
Price / Book10.25
Return on Equity-51.72%
Return on Assets-43.55%
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) posted its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.86) by $0.66. The biotechnology company earned $45.95 million during the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same quarter last year, the firm posted ($0.95) EPS. View Sarepta Therapeutics' Earnings History.
When will Sarepta Therapeutics make its next earnings announcement?
Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2018?
19 analysts have issued 1 year price objectives for Sarepta Therapeutics' shares. Their forecasts range from $27.00 to $101.00. On average, they anticipate Sarepta Therapeutics' share price to reach $68.84 in the next twelve months. View Analyst Ratings for Sarepta Therapeutics.
What are Wall Street analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- 1. According to Zacks Investment Research, "Sarepta's Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year. Loss estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (2/7/2018)
- 2. Cowen Inc analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
- 3. Instinet analysts commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant upside to materialize as Exondys 51 launch metrics begin to reflect an underestimated demand for the treatment and the ultimate patient numbers/market opportunity. We expect additional upside to be realized following EU approval of Exondys 51, which will help bolster perception of the drug's benefit and to define the EU opportunity, currently not reflected in shares." (3/1/2017)
- 4. Needham & Company LLC analysts commented, "As previously reported, Sarepta earned $5.4M in 4Q16 Exondys revenue. The company gave 1Q and FY17 guidance for Exondys sales of $13-15M and >$80M, respectively. While the 1Q guidance number is relatively in line with our ($17M) and the Street's estimates, the low end of FY17 guidance is significantly below expectations and implies no acceleration in new patient starts through the back part of 2017. This sales guidance contrasts with management's qualitative commentary about accelerating conversion rates and we believe is explained by conservatism in an uncertain and dynamic reimbursement environment. We continue to expect that the majority of the 1,400+ eligible DMD boys in the US will ultimately be on therapy by implying a ~$400M Exondys US sales run rate." (3/1/2017)
- 5. Royal Bank of Canada analysts commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT -15%AH). We didn't hear anything on the call to justify this level of selling: while FY17 guidance appears soft to us (>$80M) and doesn't exude confidence, guidance for 1Q17 ($13-$15 vs. $5.4M in 4Q16) and management's language about conversion rate acceleration, makes us view the >$80M guidance as beatable." (3/1/2017)
Are investors shorting Sarepta Therapeutics?
Sarepta Therapeutics saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 9,146,812 shares, a drop of 15.3% from the January 12th total of 10,804,883 shares. Based on an average daily trading volume, of 1,590,305 shares, the short-interest ratio is currently 5.8 days. Currently, 15.1% of the shares of the company are sold short.
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include Beigene (BGNE), Neurocrine Biosciences (NBIX), Shire-Nps Pharmaceuticals (NPSP), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Array BioPharma (ARRY), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Auspex Pharmaceuticals (ASPX), Loxo Oncology (LOXO), AnaptysBio (ANAB), Clovis Oncology (CLVS), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma A/S (ASND) and Myokardia (MYOK).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Douglas S. Ingram, President, Chief Executive Officer (Age 54)
- Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer (Age 52)
- David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary (Age 45)
- Alexander Cumbo, Senior Vice President, Global Commercial Development (Age 46)
- Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality (Age 57)
- Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer (Age 54)
- Michael W. Bonney, Director (Age 59)
- Richard J. Barry, Independent Director (Age 58)
- M. Kathleen Behrens Ph.D., Independent Director (Age 64)
- Claude Nicaise M.D., Independent Director (Age 64)
Who owns Sarepta Therapeutics stock?
Sarepta Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.73%), Fred Alger Management Inc. (2.45%), HealthCor Management L.P. (2.03%), Jennison Associates LLC (1.78%), Eagle Asset Management Inc. (1.53%) and Emerald Advisers Inc. PA (1.37%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Jayant Aphale, M Kathleen Behrens, Sandesh Mahatme and Shamim Ruff. View Institutional Ownership Trends for Sarepta Therapeutics.
Who sold Sarepta Therapeutics stock? Who is selling Sarepta Therapeutics stock?
Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Quantitative Investment Management LLC, Tekla Capital Management LLC, Sphera Funds Management LTD., HealthCor Management L.P., J. Goldman & Co LP, Alliancebernstein L.P. and QVT Financial LP. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, Edward M Md Kaye, Hans Lennart Rudolf Wigzell, Sandesh Mahatme and Shamim Ruff. View Insider Buying and Selling for Sarepta Therapeutics.
Who bought Sarepta Therapeutics stock? Who is buying Sarepta Therapeutics stock?
Sarepta Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Gilder Gagnon Howe & Co. LLC, Element Capital Management LLC, Sectoral Asset Management Inc, Fuller & Thaler Asset Management Inc., Fred Alger Management Inc., Stansberry Asset Management LLC and Alps Advisors Inc.. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram and M Kathleen Behrens. View Insider Buying and Selling for Sarepta Therapeutics.
How do I buy Sarepta Therapeutics stock?
Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of Sarepta Therapeutics stock can currently be purchased for approximately $63.22.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $4.17 billion and generates $5.42 million in revenue each year. The biotechnology company earns $-267,260,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Sarepta Therapeutics employs 197 workers across the globe.
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 1st St Ste 415, CAMBRIDGE, MA 02142-1213, United States. The biotechnology company can be reached via phone at +1-617-2744000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (SRPT)MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sarepta Therapeutics (NASDAQ:SRPT) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.89||2.84||2.79||2.85|
|Ratings Breakdown: ||0 Sell Rating(s)|
2 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
4 Hold Rating(s)
15 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$68.84||$66.79||$65.61||$62.50|
|Price Target Upside: ||9.50% upside||7.07% upside||37.72% upside||54.02% upside|
Sarepta Therapeutics (NASDAQ:SRPT) Consensus Price Target History
Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History
(Data available from 2/21/2016 forward)
Sarepta Therapeutics (NASDAQ:SRPT) Earnings History and Estimates Chart
Sarepta Therapeutics (NASDAQ SRPT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|10/25/2017||Q3 2017||($0.86)||($0.20)||$41.29 million||$45.95 million||View||N/A|
|7/19/2017||Q2 2017||($0.92)||($0.46)||$22.52 million||$35.01 million||View||N/A|
|4/27/2017||Q1 2017||($0.85)||($0.73)||$13.80 million||$16.34 million||View||N/A|
|2/28/2017||Q416||($1.33)||($0.71)||$4.86 million||$5.42 million||View||Listen|
|8/6/2015||Q215||($1.21)||($1.01)||$0.31 million||$0.01 million||View||Listen|
|2/26/2015||Q414||($0.82)||($0.94)||$1.56 million||$0.30 million||View||Listen|
|11/6/2014||Q314||($0.96)||($0.70)||$3.07 million||$1.10 million||View||Listen|
|8/7/2014||Q214||($0.76)||($0.85)||$4.30 million||$2.58 million||View||Listen|
|5/8/2014||Q114||($0.80)||($0.75)||$3.45 million||$6.09 million||View||Listen|
|2/27/2014||Q413||($0.69)||($0.77)||$4.53 million||$2.60 million||View||Listen|
|11/12/2013||Q313||($0.65)||($0.63)||$4.57 million||$4.20 million||View||Listen|
|8/8/2013||Q2 2013||($0.67)||($0.46)||$5.08 million||$3.00 million||View||Listen|
|5/9/2013||Q1 2013||($0.62)||($0.41)||$5.85 million||$4.50 million||View||Listen|
|3/7/2013||Q4 2012||($0.26)||($2.36)||$6.71 million||$7.30 million||View||Listen|
|11/7/2012||($0.27)||($2.17)||$10.06 million||$7.57 million||View||N/A|
Sarepta Therapeutics (NASDAQ:SRPT) Earnings Estimates
2018 EPS Consensus Estimate: ($1.05)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by MarketBeat.com
Sarepta Therapeutics (NASDAQ SRPT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 86.62%
Sarepta Therapeutics (NASDAQ SRPT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/30/2017||Hans Lennart Rudolf Wigzell||Director||Sell||6,667||$55.89||$372,618.63||13,333|| |
|11/8/2017||Douglas S Ingram||CEO||Buy||38,138||$52.44||$1,999,956.72||420,196|| |
|11/6/2017||Shamim Ruff||SVP||Sell||10,000||$55.00||$550,000.00||37,045|| |
|10/3/2017||Shamim Ruff||SVP||Sell||11,500||$50.00||$575,000.00|| |
|7/27/2017||Douglas S Ingram||CEO||Buy||47,058||$42.50||$1,999,965.00||382,058|| |
|7/21/2017||Shamim Ruff||SVP||Sell||12,138||$42.97||$521,569.86||27,312|| |
|7/20/2017||Alexander Cumbo||SVP||Sell||5,918||$41.00||$242,638.00||22,793|| |
|7/20/2017||Edward M Md Kaye||Director||Sell||10,000||$41.00||$410,000.00||62,471|| |
|7/20/2017||Sandesh Mahatme||CFO||Sell||50,000||$41.00||$2,050,000.00||41,736|| |
|10/17/2016||Sandesh Mahatme||Insider||Sell||30,000||$50.08||$1,502,400.00||61,532|| |
|9/22/2016||David T Howton||SVP||Sell||7,000||$60.00||$420,000.00||28,453|| |
|9/22/2016||Edward M Md Kaye||CEO||Sell||40,179||$60.00||$2,410,740.00||117,162|| |
|9/19/2016||David T Howton||SVP||Sell||9,304||$50.00||$465,200.00||11,168|| |
|9/19/2016||Edward M Md Kaye||CEO||Sell||24,352||$50.00||$1,217,600.00||89,983|| |
|9/19/2016||Jayant Aphale||VP||Sell||35,000||$50.00||$1,750,000.00||21,490|| |
|9/14/2016||Edward M Md Kaye||CEO||Sell||24,557||$30.00||$736,710.00||76,983|| |
|3/16/2016||M Kathleen Behrens||Director||Buy||10,000||$14.54||$145,400.00||112,166|| |
|3/14/2016||M Kathleen Behrens||Director||Buy||65,000||$16.54||$1,075,100.00||112,166|| |
|11/14/2013||Anthony Chase||Director||Buy||10,000||$13.95||$139,500.00||41,744|| |
|9/16/2013||M Kathleen Behrens||Director||Buy||6,500||$37.04||$240,760.00||44,166|| |
|9/3/2013||John Hodgman||Director||Sell||5,556||$34.97||$194,293.32|| |
|8/22/2013||Anthony Chase||Director||Buy||3,500||$32.68||$114,380.00||31,744|| |
|8/20/2013||Sandesh Mahatme||CFO||Buy||5,000||$31.10||$155,500.00||5,000|| |
|6/14/2013||Anthony R Chase||Director||Buy||10,000||$38.50||$385,000.00|| |
|9/7/2012||M Kathleen Behrens||Director||Buy||17,500||$14.73||$257,775.00|| |
Sarepta Therapeutics (NASDAQ SRPT) News Headlines
|Sarepta Therapeutics (SRPT) Upgraded by BidaskClub to Buy|
www.americanbankingnews.com - February 21 at 7:42 PM
| Analysts Anticipate Sarepta Therapeutics Inc (SRPT) to Announce -$0.35 EPS|
www.americanbankingnews.com - February 21 at 7:14 PM
|JPMorgan Chase & Co. Reaffirms "Overweight" Rating for Sarepta Therapeutics (SRPT)|
www.americanbankingnews.com - February 21 at 10:58 AM
|Sarepta Therapeutics (SRPT) Set to Announce Earnings on Monday|
www.americanbankingnews.com - February 19 at 5:04 AM
|Sarepta Therapeutics: Doubling Down On The Pullback - Seeking Alpha|
seekingalpha.com - February 14 at 8:17 AM
|New Research: Key Drivers of Growth for Morgan Stanley, Novavax, Xerox, Sarepta Therapeutics, Semgroup, and Toll Brothers — Factors of Influence, Major Initiatives and Sustained Production|
finance.yahoo.com - February 14 at 8:17 AM
|Sarepta Therapeutics (SRPT) Given a $75.00 Price Target at HC Wainwright|
www.americanbankingnews.com - February 12 at 8:28 PM
|Stock Review for Biotech's Investors -- Sage Therapeutics, Sarepta Therapeutics, Sierra Oncology, and Sorrento Therapeutics|
www.prnewswire.com - February 12 at 8:10 AM
|Sarepta Therapeutics (SRPT) Downgraded to Hold at BidaskClub|
www.americanbankingnews.com - February 10 at 8:50 AM
|Sarepta Therapeutics Inc (SRPT) Short Interest Down 15.3% in January|
www.americanbankingnews.com - February 10 at 1:40 AM
|Pre-Open Movers 02/09: (PIRS) (FEYE) (NVDA) Higher; (TNDM) (EXPE) (WWD) Lower (more...)|
www.streetinsider.com - February 9 at 3:43 PM
|Sarepta stock drops 6% after report of halted trial due to 'serious adverse event'|
finance.yahoo.com - February 9 at 3:43 PM
|Sarepta shares plunge on U.K. trial halt, but analyst downplays safety fears|
finance.yahoo.com - February 9 at 3:43 PM
|Why Sarepta Therapeutics Inc Stock is Sliding Today|
investorplace.com - February 9 at 12:24 PM
|Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Developments on March 1, 2018|
finance.yahoo.com - February 8 at 3:33 PM
|Bringing The Human Element Full Circle Thru Adaptive Ski Coaching|
finance.yahoo.com - February 8 at 8:01 AM
|Sarepta Therapeutics (SRPT) Upgraded by Zacks Investment Research to "Hold"|
www.americanbankingnews.com - February 7 at 1:12 PM
|Sarepta Therapeutics Inc (SRPT) to Post FY2017 Earnings of ($3.04) Per Share, William Blair Forecasts|
www.americanbankingnews.com - February 7 at 6:46 AM
|Sarepta Therapeutics Inc (SRPT) Expected to Announce Quarterly Sales of $57.49 Million|
www.americanbankingnews.com - February 6 at 4:28 AM
|William Blair Reiterates Outperform Rating for Sarepta Therapeutics (SRPT)|
www.americanbankingnews.com - February 5 at 6:30 PM
|Sarepta Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference|
finance.yahoo.com - February 5 at 3:32 PM
|Sarepta Therapeutics Inc (SRPT) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - February 2 at 1:46 PM
|Gene therapy stocks slammed after scientist reveals safety concerns - MarketWatch|
www.marketwatch.com - January 30 at 3:34 PM
|Gene therapy stocks slammed after scientist reveals safety concerns|
finance.yahoo.com - January 30 at 3:34 PM
|[$$] Scholarly Article Proves Toxic to Gene-Therapy Stocks|
finance.yahoo.com - January 30 at 3:34 PM
|Sarepta Therapeutics: Still The Best Option In The DMD Space - Seeking Alpha|
seekingalpha.com - January 30 at 7:58 AM
|Solid Biosciences Completes IPO|
finance.yahoo.com - January 26 at 3:34 PM
|Solid Biosciences, Sarepta Square Off In Fight to Treat Duchenne - Barron's|
www.barrons.com - January 25 at 3:35 PM
|Biotechnology Companies Prepared for a Big 2018 - PR Newswire (press release)|
www.prnewswire.com - January 25 at 3:35 PM
|[$$] Solid Biosciences' IPO Hits Potential Snag|
finance.yahoo.com - January 25 at 3:34 PM
|Sarepta Therapeutics Inc to Post FY2020 Earnings of $2.91 Per Share, Leerink Swann Forecasts (SRPT)|
www.americanbankingnews.com - January 24 at 9:02 PM
|[$$] Solid Biosciences, Sarepta Square Off In Fight to Treat Duchenne|
finance.yahoo.com - January 24 at 3:40 PM
|Barclays Reaffirms Hold Rating for Sarepta Therapeutics (SRPT)|
www.americanbankingnews.com - January 23 at 10:06 PM
|In This Booming Stock Market, Think Like a Programmer Not a Critic|
finance.yahoo.com - January 22 at 3:43 PM
|Sarepta Therapeutics Inc Expected to Earn FY2020 Earnings of $2.91 Per Share (SRPT)|
www.americanbankingnews.com - January 22 at 2:52 PM
|Sarepta Therapeutics (SRPT) Rating Reiterated by Leerink Swann|
www.americanbankingnews.com - January 20 at 4:08 PM
|First Duchenne Muscular Dystrophy Patient Dosed in Systemic Microdystrophin Gene Therapy|
www.prnewswire.com - January 17 at 3:33 PM
|Sarepta: Rosy Prospects Continue, Buying On Dips - Seeking Alpha|
seekingalpha.com - January 15 at 3:33 PM
|Sarepta Therapeutics Sees Unusually High Options Volume (SRPT)|
www.americanbankingnews.com - January 15 at 6:16 AM
|Sarepta Therapeutics (SRPT) Upgraded at BidaskClub|
www.americanbankingnews.com - January 13 at 12:28 PM
|You Can't Reason With a Steamroller|
finance.yahoo.com - January 12 at 3:31 PM
|Sarepta is making a bold bet on genetic medicine|
finance.yahoo.com - January 10 at 3:33 PM
|Sarepta Therapeutics: Continued Upside In 2018 - Seeking Alpha|
seekingalpha.com - January 10 at 11:37 AM
|Sarepta Therapeutics' (SRPT) Buy Rating Reiterated at HC Wainwright|
www.americanbankingnews.com - January 9 at 12:50 PM
|Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue|
www.nasdaq.com - January 8 at 4:07 PM
|Sarepta Therapeutics (SRPT) Sees Q4 Revenue of $57.3M, Modestly Above the Street - StreetInsider.com|
www.streetinsider.com - January 8 at 3:38 PM
|Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth|
finance.yahoo.com - January 8 at 3:38 PM
|Sarepta Therapeutics Inc (SRPT) Receives Average Recommendation of "Buy" from Brokerages|
www.americanbankingnews.com - January 8 at 2:44 PM
|Today’s Research Reports on Stocks to Watch: Sarepta Therapeutics and Valeant Pharmaceuticals|
finance.yahoo.com - January 8 at 9:20 AM
|Q1 2018 Earnings Estimate for Sarepta Therapeutics Inc (SRPT) Issued By Leerink Swann|
www.americanbankingnews.com - January 8 at 4:38 AM
Sarepta Therapeutics (NASDAQ:SRPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sarepta Therapeutics (NASDAQ:SRPT) Income Statement, Balance Sheet and Cash Flow Statement
Sarepta Therapeutics (NASDAQ SRPT) Stock Chart for Wednesday, February, 21, 2018